Publications Repository

Publications Repository

View Item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View Item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.

Thumbnail
View/Open
Accepted version (600.7Kb)
Publication Date
2020-08
ICR Author
Larkin, James
Author
Maio, M
Hamid, O
Larkin, J
Covre, A
Altomonte, M
Calabrò, L
Vardhana, SA
Robert, C
Ibrahim, R
Anichini, A
Wolchok, JD
Giacomo, AMD
Type
Journal Article
Metadata
Show full item record
Abstract
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
URL
https://repository.icr.ac.uk/handle/internal/4130
Collections
  • Clinical Studies
Licenseref URL
http://www.rioxx.net/licenses/under-embargo-all-rights-reserved
Version of record
10.1158/1078-0432.ccr-20-1657
Subject
Humans
Pneumonia, Viral
Coronavirus Infections
Neoplasms
Treatment Outcome
Clinical Trials as Topic
Pandemics
CTLA-4 Antigen
Programmed Cell Death 1 Receptor
Clinical Decision-Making
Betacoronavirus
Antineoplastic Agents, Immunological
B7-H1 Antigen
COVID-19
SARS-CoV-2
Research team
Melanoma and Kidney Cancer
Language
eng
Date accepted
2020-06-09
License start date
2020-08
Citation
Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 26 (16), pp. 4201 - 4205

Browse

All of ICR repositoryICR DivisionsIssue dateAuthorsTitlesSubjectsThis collectionIssue dateAuthorsTitlesSubjects

Statistics

Most popular itemsStatistics by countryMost popular authors
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.